Top

BMC Geriatrics

Published in:

01-12-2021 | Obesity | Research

Muscle strength, an independent determinant of glycemic control in older adults with long-standing type 2 diabetes: a prospective cohort study

Authors: Bo Kyung Koo, Seoil Moon, Min Kyong Moon

Published in: BMC Geriatrics | Issue 1/2021

Abstract

Background

Although the proportion of older patients with type 2 diabetes mellitus (T2DM) has increased, few studies have reported the factors affecting glucose levels in older patients with long-standing T2DM. This study assessed the determinants of glycemic control in older adults with T2DM of a duration of ≥10 years, including muscle mass, muscle quality, and β-cell function.

Methods

This was a prospective study of older patients aged ≥60 years with a T2DM duration of ≥10 years. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index, handgrip strength (HGS), and body composition through bioelectrical impedance analysis were assessed. The primary outcome was a composite of: (i) increment of glycated hemoglobin (HbA1c) from the baseline ≥0.6% and (ii) HbA1c ≥ 9% at any time point during the follow-up period. To find the predicting determinants of the outcome, we performed the Cox proportional hazard analysis.

Results

Among 100 patients (mean age, 64.0 ± 8.6 years; median duration of diabetes, 20 [interquartile range (IQR), 17–23] years; median HbA1c at baseline, 7.1 [IQR, 6.7–7.4] %), the primary outcome was observed in 40 (40.0%) patients during 4.0 (IQR 2.3–5.0) years of follow-up. A Cox proportional hazards model adjusted for age, sex, baseline HbA1c, obesity, duration of DM and anti-diabetic medication at baseline showed that low HGS and insulin resistance at the baseline were independent determinants of the primary outcome (hazard ratio [HR] = 2.23 [95% confidence interval (CI), 1.06–4.72] and 2.39 [95% CI, 1.18–4.83], respectively). Sex stratification confirmed that HGS and muscle mass were independent determinants of the primary outcome only in women (HR per quartile, 0.58 [95% CI, 0.37–0.93] and 0.46 [95% CI, 0.25–0.85], respectively). `.

Conclusions

Low HGS and insulin resistance were independent risk factors for aggravated glycemic control among older patients with long standing T2DM.

Available only for authorised users

Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM. 2003;96(4):281–8 https://doi.org/10.1093/qjmed/hcg040.CrossRefPubMed

Hayashino Y, Izumi K, Okamura S, Nishimura R, Origasa H, Tajima N, et al. Duration of diabetes and types of diabetes therapy in Japanese patients with type 2 diabetes: the Japan diabetes complication and its prevention prospective study 3 (JDCP study 3). J Diabetes Investig. 2017;8(2):243–9 https://doi.org/10.1111/jdi.12550.CrossRefPubMed

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–43 https://doi.org/10.1056/NEJMoa066224.CrossRefPubMed

Fang M, Echouffo-Tcheugui JB, Selvin E. Clinical and public health implications of 2019 Endocrine Society guidelines for diagnosis of diabetes in older adults. Diabetes Care. 2020;43(7):1456–61 https://doi.org/10.2337/dc19-2467.CrossRefPubMedPubMedCentral

Jung CH, Son JW, Kang S, Kim WJ, Kim HS, Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021;45(1):1–10 https://doi.org/10.4093/dmj.2020.0254.CrossRefPubMedPubMedCentral

Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251–8 https://doi.org/10.1001/jamainternmed.2013.12956.CrossRefPubMedPubMedCentral

Del Prato S, Foley JE, Kothny W, Kozlovski P, Stumvoll M, Paldanius PM, et al. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabet Med. 2014;31(10):1178–84 https://doi.org/10.1111/dme.12508.CrossRefPubMedPubMedCentral

Mamo Y, Bekele F, Nigussie T, Zewudie A. Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University medical center, Jimma zone, south West Ethiopia: a case control study. BMC Endocr Disord. 2019;19(1):91 https://doi.org/10.1186/s12902-019-0421-0.CrossRefPubMedPubMedCentral

Kim YG, Park DG, Moon SY, Jeon JY, Kim HJ, Kim DJ, et al. Hypoglycemia and dementia risk in older patients with type 2 diabetes mellitus: a propensity-score matched analysis of a population-based cohort study. Diabetes Metab J. 2020;44(1):125–33 https://doi.org/10.4093/dmj.2018.0260.CrossRefPubMed

10.

Dziedzic B, Sienkiewicz Z, Lenczuk-Gruba A, Kobos E, Fidecki W, Wysokiski M. Prevalence of Depressive Symptoms in the Elderly Population Diagnosed with Type 2 Diabetes Mellitus. Int J Environ Res Public Health. 2020;17(10). https://doi.org/10.3390/ijerph17103553.

11.

Lee PG, Halter JB. The pathophysiology of hyperglycemia in older adults: clinical considerations. Diabetes Care. 2017;40(4):444–52 https://doi.org/10.2337/dc16-1732.CrossRefPubMed

12.

American DA. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596–615 https://doi.org/10.2337/dc08-9017.CrossRef

13.

Aguayo-Mazzucato C, Andle J, Lee TB Jr, Midha A, Talemal L, Chipashvili V, et al. Acceleration of beta cell aging determines diabetes and Senolysis improves disease outcomes. Cell Metab. 2019;30(1):129–42 e4 https://doi.org/10.1016/j.cmet.2019.05.006.CrossRefPubMedPubMedCentral

14.

Koo BK, Roh E, Yang YS, Moon MK. Difference between old and young adults in contribution of beta-cell function and sarcopenia in developing diabetes mellitus. J Diabetes Investig. 2016;7(2):233–40 https://doi.org/10.1111/jdi.12392.CrossRefPubMed

15.

Sugimoto K, Tabara Y, Ikegami H, Takata Y, Kamide K, Ikezoe T, et al. Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: the multicenter study for clarifying evidence for sarcopenia in patients with diabetes mellitus. J Diabetes Investig. 2019;10(6):1471–9 https://doi.org/10.1111/jdi.13070.CrossRefPubMedPubMedCentral

16.

Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, et al. 2019 clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019;43(4):398–406 https://doi.org/10.4093/dmj.2019.0137.CrossRefPubMedPubMedCentral

17.

American DA. 12. Older adults: standards of medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S168–S79 https://doi.org/10.2337/dc21-S012.CrossRef

18.

Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30–7 https://doi.org/10.1111/dom.12174.CrossRefPubMed

19.

Wang B, Sun Y, Sang Y, Liu X, Liang J. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system review and meta-analysis. Medicine (Baltimore). 2018;97(46):e12633 https://doi.org/10.1097/MD.0000000000012633.CrossRef

20.

Cho YK, Kang YM, Lee SE, Lee J, Park JY, Lee WJ, et al. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2018;44(5):393–401 https://doi.org/10.1016/j.diabet.2018.01.011.CrossRefPubMed

21.

Wang N, Yang T, Li J, Zhang X. Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Metab Syndr Obes. 2019;12:1513–26 https://doi.org/10.2147/DMSO.S202024.CrossRefPubMedPubMedCentral

22.

Singh B, Saxena A. Surrogate markers of insulin resistance: a review. World J Diabetes. 2010;1(2):36–47 https://doi.org/10.4239/wjd.v1.i2.36.CrossRefPubMedPubMedCentral

23.

Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care. 2009;32(12):2297–9 https://doi.org/10.2337/dc09-0574.CrossRefPubMedPubMedCentral

24.

Pacific WHOROftW. The Asia-Pacific perspective : redefining obesity and its treatment: Australia : health communications Australia; 2000.

25.

Nam GE, Kim YH, Han K, Jung JH, Rhee EJ, Lee SS, et al. Obesity fact sheet in Korea, 2019: prevalence of obesity and abdominal obesity from 2009 to 2018 and social factors. J Obes Metab Syndr. 2020;29(2):124–32 https://doi.org/10.7570/jomes20058.CrossRefPubMedPubMedCentral

26.

Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109(23):2818–25 https://doi.org/10.1161/01.CIR.0000132467.45278.59.CrossRefPubMed

27.

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRefPubMed

28.

Koo BK. The differential association between muscle strength and diabetes mellitus according to the presence or absence of obesity. J Obes Metab Syndr. 2019;28(1):46–52 https://doi.org/10.7570/jomes.2019.28.1.46.CrossRefPubMedPubMedCentral

29.

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31 https://doi.org/10.1093/ageing/afy169.CrossRefPubMed

30.

Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007;30(6):1507–12 https://doi.org/10.2337/dc06-2537.CrossRefPubMed

31.

Yoon JW, Ha YC, Kim KM, Moon JH, Choi SH, Lim S, et al. Hyperglycemia is associated with impaired muscle quality in older men with diabetes: the Korean longitudinal study on health and aging. Diabetes Metab J. 2016;40(2):140–6 https://doi.org/10.4093/dmj.2016.40.2.140.CrossRefPubMedPubMedCentral

32.

Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–46 https://doi.org/10.1016/s0140-6736(19)31138-9.CrossRefPubMed

33.

Kunutsor SK, Isiozor NM, Khan H, Laukkanen JA. Handgrip strength-a risk indicator for type 2 diabetes: systematic review and meta-analysis of observational cohort studies. Diabetes Metab Res Rev. 2021;37(2):e3365 https://doi.org/10.1002/dmrr.3365.CrossRefPubMed

34.

Wander PL, Boyko EJ, Leonetti DL, McNeely MJ, Kahn SE, Fujimoto WY. Greater hand-grip strength predicts a lower risk of developing type 2 diabetes over 10 years in leaner Japanese Americans. Diabetes Res Clin Pract. 2011;92(2):261–4 https://doi.org/10.1016/j.diabres.2011.01.007.CrossRefPubMedPubMedCentral

35.

Lee J, Kim D, Kim C. Resistance training for glycemic control, muscular strength, and lean body mass in old type 2 diabetic patients: a Meta-analysis. Diabetes Ther. 2017;8(3):459–73 https://doi.org/10.1007/s13300-017-0258-3.CrossRefPubMedPubMedCentral

36.

Artero EG. Lee D-c, Lavie CJ, España-Romero V, sui X, church TS, et al. effects of muscular strength on cardiovascular risk factors and prognosis. Journal of Cardiopulmonary Rehabilitation and Prevention. 2012;32(6):351–8 https://doi.org/10.1097/HCR.0b013e3182642688.CrossRefPubMedPubMedCentral

37.

Koo BK, Moon MK. Are we in the same risk of diabetes mellitus? Gender- and age-specific epidemiology of diabetes in 2001 to 2014 in the Korean population. Diabetes Metab J. 2016;40(3):175–81 https://doi.org/10.4093/dmj.2016.40.3.175.CrossRefPubMedPubMedCentral

38.

Koo BK, Kim SW, Yi KH, Park KS, Moon MK. Changing relative contribution of abdominal obesity and a family history of diabetes on prevalence of diabetes mellitus in Korean men and women aged 30-49 years from 2001 to 2010. J Diabetes. 2015;7(4):465–72 https://doi.org/10.1111/1753-0407.12202.CrossRefPubMed

39.

Fasanmade OA, Okubadejo NU. Magnitude and gender distribution of obesity and abdominal adiposity in Nigerians with type 2 diabetes mellitus. Niger J Clin Pract. 2007;10(1):52–7.PubMed

40.

Koo BK, Kim SW, Yi KH, Moon MK. Low economic status is identified as an emerging risk factor for diabetes mellitus in korean men aged 30 to 59 years in korean national health and nutrition examination survey 2008 to 2010. Diabetes Metab J. 2015;39(2):137–46 https://doi.org/10.4093/dmj.2015.39.2.137.CrossRefPubMedPubMedCentral

41.

Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260 https://doi.org/10.3389/fphys.2012.00260.CrossRefPubMedPubMedCentral

42.

Kang S, Oh TJ, Cho BL, Park YS, Roh E, Kim HJ, et al. Sex differences in sarcopenia and frailty among community-dwelling Korean older adults with diabetes: the Korean frailty and aging cohort study. J Diabetes Investig. 2021;12(2):155–64 https://doi.org/10.1111/jdi.13348.CrossRefPubMed

43.

de Freitas MM, de Oliveira VLP, Grassi T, Valduga K, Miller MEP, Schuchmann RA, et al. Difference in sarcopenia prevalence and associated factors according to 2010 and 2018 European consensus (EWGSOP) in elderly patients with type 2 diabetes mellitus. Exp Gerontol. 2020;132:110835 https://doi.org/10.1016/j.exger.2020.110835.CrossRefPubMed

44.

Fukuoka Y, Narita T, Fujita H, Morii T, Sato T, Sassa MH, et al. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. J Diabetes Investig. 2019;10(2):322–30 https://doi.org/10.1111/jdi.12908.CrossRefPubMed

45.

Chen F, Xu S, Wang Y, Chen F, Cao L, Liu T, et al. Risk factors for sarcopenia in the elderly with type 2 diabetes mellitus and the effect of metformin. J Diabetes Res. 2020;2020:3950404 https://doi.org/10.1155/2020/3950404.CrossRefPubMedPubMedCentral

46.

Gunasekaran U, Gannon M. Type 2 diabetes and the aging pancreatic beta cell. Aging (Albany NY). 2011;3(6):565–75. https://doi.org/10.18632/aging.100350.CrossRef

47.

Sugimoto K, Ikegami H, Takata Y, Katsuya T, Fukuda M, Akasaka H, et al. Glycemic control and insulin improve muscle mass and gait speed in type 2 diabetes: the MUSCLES-DM study. J Am Med Dir Assoc. 2021;22(4):834–8 e1 https://doi.org/10.1016/j.jamda.2020.11.003.CrossRefPubMed

48.

Yang YS, Kwak SH, Park KS. Update on monogenic diabetes in Korea. Diabetes Metab J. 2020;44(5):627–39 https://doi.org/10.4093/dmj.2020.0214.CrossRefPubMedPubMedCentral

49.

Yamamoto S, Hotta K, Ota E, Mori R, Matsunaga A. Effects of resistance training on muscle strength, exercise capacity, and mobility in middle-aged and elderly patients with coronary artery disease: a meta-analysis. J Cardiol. 2016;68(2):125–34 https://doi.org/10.1016/j.jjcc.2015.09.005.CrossRefPubMed

50.

Liao W. Chen Jw, Chen X, Lin L, Yan Hy, Zhou Yq, et al. impact of resistance training in subjects with COPD: a systematic review and Meta-analysis. Respir Care. 2015;60(8):1130–45 https://doi.org/10.4187/respcare.03598.CrossRefPubMed

Title: Muscle strength, an independent determinant of glycemic control in older adults with long-standing type 2 diabetes: a prospective cohort study
Authors: Bo Kyung Koo
Seoil Moon
Min Kyong Moon
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Obesity
Obesity
Sarcopenia
Insulins
Diabetes
Insulins
Type 2 Diabetes
Published in: BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-021-02629-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

The Framingham risk score is associated with incident frailty, or is it?

Factors associated with physical, psychological and social frailty among community-dwelling older persons in Europe: a cross-sectional study of Urban Health Centres Europe (UHCE)

Associations between nut intake, cognitive function and non‐alcoholic fatty liver disease (NAFLD) in older adults in the United States: NHANES 2011-14

Effects of a culturally adapted group based Montessori based activities on engagement and affect in Chinese older people with dementia: a randomized controlled trial

Effects of physician visit frequency for Parkinson’s disease treatment on mortality, hospitalization, and costs: a retrospective cohort study

Use of health and aged care services in Australia following hospital admission for myocardial infarction, stroke or heart failure

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage